Suppr超能文献

新冠感染后肺移植患者的临床-放射-病理特征和结局:单中心经验。

Clinico-Radiological-Pathologic Profile and Outcomes of Lung Transplant in Post-COVID-19 Phenotype: A Single Center Experience.

机构信息

Department of Transplant Pulmonology, Krishna Institute of Medical Sciences, Secunderabad, India.

Department of Transplant Pulmonology, Krishna Institute of Medical Sciences, Secunderabad, India.

出版信息

Transplant Proc. 2022 Jul-Aug;54(6):1494-1503. doi: 10.1016/j.transproceed.2022.03.007. Epub 2022 Apr 11.

Abstract

BACKGROUND

Lung transplantation (LTx) has come as hope for select patients with post-COVID acute respiratory distress syndrome (ARDS). It has a different phenotype with unique challenges. We aimed to bring out our experience with and outcomes of LTx for post-COVID ARDS.

METHODS

This study is retrospective case series from a single center in India. All the patients with post-COVID end stage lung disease (ESLD) who underwent bilateral LTx between 1st May 2020 and 30th August 2021 were included. LTx was performed following no improvement with optimal medical management with adequate time provided for recovery. Information relating to demographics, comorbidities, pretransplant status, perioperative parameters, gross and histopathological findings of explanted lungs, posttransplant morbidity, and mortality were analyzed.

RESULTS

This study included 23 patients. The median age of the patients in this study was 42 years and 20 participants were men (87%). The mean duration of intensive care unit stay was 15.83 ± 6.61 days. Mortality was observed among 8 participants (34.78%). Mean survival time was 34.54 weeks. Among the 8 patients who expired, the cause of death was sepsis for 6 patients (75.0%), neurologic cerebrovascular accident for 1 patient (12.5%), and cytomegalovirus for 1 patient (12.5%). All the deaths were reported in primary graft dysfunction grade 2 & 3 category. No rejections were observed on first and third month surveillance biopsies.

CONCLUSIONS

LTx is the definitive option for survival in select patients with severe post-COVID-19-associated ESLD. This study brings out various challenges involved in such phenotypes and also observations in postoperative recovery.

摘要

背景

肺移植(LTx)为患有 COVID-19 后急性呼吸窘迫综合征(ARDS)的特定患者带来了希望。它具有不同的表型,存在独特的挑战。我们旨在介绍我们在 COVID-19 后 ARDS 患者中行 LTx 的经验和结果。

方法

这是印度一家单中心的回顾性病例系列研究。纳入了所有在 2020 年 5 月 1 日至 2021 年 8 月 30 日期间因 COVID-19 终末期肺病(ESLD)而行双侧 LTx 的患者。LTx 是在最佳药物治疗无改善且为恢复提供了足够时间后进行的。分析了人口统计学、合并症、移植前状态、围手术期参数、移植肺的大体和组织病理学发现、移植后发病率和死亡率等信息。

结果

这项研究共纳入了 23 例患者。该研究患者的中位年龄为 42 岁,20 例为男性(87%)。重症监护病房的平均停留时间为 15.83±6.61 天。8 例患者(34.78%)观察到死亡。平均生存时间为 34.54 周。在 8 例死亡患者中,6 例(75.0%)的死亡原因为败血症,1 例(12.5%)为神经脑血管意外,1 例(12.5%)为巨细胞病毒。所有死亡均发生在原发性移植物功能障碍 2 级和 3 级。第一次和第三次监测活检均未观察到排斥反应。

结论

LTx 是治疗 COVID-19 后严重相关 ESLD 患者的首选方法。本研究介绍了此类表型所涉及的各种挑战,以及术后恢复的观察结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d067/8995303/23613c15dd95/gr1_lrg.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验